公开(公告)号：US20130064760A1

公开(公告)日：2013-03-14

申请号：US13670918

申请日：2012-11-07

Applicant: JANSSEN BIOTECH, INC.

Inventor： Jill Giles-Komar ,  David M. Knight ,  David Peritt ,  Bernard Scallon ,  David Shealy

IPC: A61K39/395 ,  A61P17/06 ,  A61P21/02 ,  A61P29/00 ,  A61P31/00 ,  A61P37/04 ,  A61P37/06 ,  A61P23/00 ,  A61P23/02 ,  A61K51/00 ,  A61P25/20

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as Crohn's disease.

Abstract translation: 分离的抗IL-12抗体，编码抗体或抗体部分的核酸，载体，宿主细胞和制备方法可用于产生用于治疗和/或诊断IL-12相关病症，疾病和障碍的抗体或部分， 如克罗恩病。

公开(公告)号：US09828424B2

公开(公告)日：2017-11-28

申请号：US15075248

申请日：2016-03-21

Applicant: Janssen Biotech, Inc.

Inventor： George Heavner ,  David M. Knight ,  Jill Giles-Komar ,  Bernard Scallon ,  David Shealy

IPC: C07K16/24 ,  A61K9/19 ,  A61K39/395 ,  A61K38/18 ,  A61K38/19 ,  A61K38/27 ,  A61K45/06 ,  C07K16/42 ,  G01N33/566 ,  A61K39/00

CPC classification number: C07K16/241 ,  A61K9/19 ,  A61K38/1816 ,  A61K38/19 ,  A61K38/27 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/42 ,  C07K16/4241 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/566 ,  Y02A50/386 ,  Y02A50/412 ,  Y10S514/825 ,  Y10S514/826

Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.

公开(公告)号：US20140178295A1

公开(公告)日：2014-06-26

申请号：US14190893

申请日：2014-02-26

Applicant: Janssen Biotech, Inc.

Inventor： Jill Giles-Komar ,  David M. Knight ,  David Peritt ,  Bernard Scallon ,  David Shealy

IPC: C07K16/24 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.

Abstract translation: 分离的抗IL-12抗体，编码抗体或抗体部分的核酸，载体，宿主细胞和制备方法可用于产生用于治疗和/或诊断IL-12相关病症，疾病和障碍的抗体或部分， 如牛皮癣。

公开(公告)号：US20140141013A1

公开(公告)日：2014-05-22

申请号：US14167384

申请日：2014-01-29

Applicant: Janssen Biotech, Inc.

Inventor： Jill Giles-Komar ,  David M. Knight ,  David Peritt ,  Mohit Trikha

IPC: C07K16/24

CPC classification number: C07K16/248 ,  A01K67/0271 ,  A01K2267/0331 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/4241 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Abstract translation: 本发明涉及至少一种衍生自鼠CLB-8抗体的新型嵌合，人源化或CDR移植的抗IL-6抗体，包括编码至少一种这样的抗IL-6抗体的分离的核酸，载体， 宿主细胞，转基因动物或植物，以及其制备和使用方法，包括治疗组合物，方法和装置。